The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Kiowa Kirin; Lilly; Merck Serono; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Pfizer; Quintiles; Roche; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Lilly; Merck Sharp & Dohme; Ono Pharmaceutical; Pfizer; Sumitomo Group; Taiho Pharmaceutical
Research Funding - Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Kiowa Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Ono Pharmaceutical (Inst); PAREXEL (Inst); Pfizer (Inst); Quintiles (Inst); Taiho Pharmaceutical (Inst)
Randomized phase III study of first-line pembrolizumab plus pemetrexed/platinum followed by pembrolizumab and maintenance olaparib versus pemetrexed in patients with metastatic nonsquamous non-small cell lung cancer (NSCLC): KEYLYNK-006.
 
Jhanelle Elaine Gray
Honoraria - AstraZeneca; Axiom Healthcare Strategies; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; EMD Serono; Genentech; Lilly; Merck; Takeda
Consulting or Advisory Role - AstraZeneca; Axiom Healthcare Strategies; Axiom Healthcare Strategies; Bristol-Myers Squibb; Celgene; EMD Serono; EMD Serono; Merck; Merck; Novartis; Takeda
Research Funding - Array BioPharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Lilly; Merck; Merck Serono; Novartis; Takeda
 
Taofeek Kunle Owonikoko
Stock and Other Ownership Interests - CAMBIUM MEDICAL TECHNOLOGIES
Consulting or Advisory Role - Abbvie; Amgen; ARMO BioSciences; AstraZeneca; Bayer; BerGenBio; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; EMD Serono; G1 Therapeutics; HERON; Lilly; Lilly; MedImmune; Merck; Novartis; PharmaMar; Sandoz; Seagen; Takeda; Xcovery
Speakers' Bureau - Abbvie
Research Funding - Abbvie (Inst); Aeglea Biotherapeutics (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca/MedImmune (Inst); Bayer (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Corvus Pharmaceuticals; Fujifilm (Inst); G1 Therapeutics (Inst); Incyte (Inst); Loxo/Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Stem CentRx (Inst); United Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - DR4 Modulation and its Implications in EGFR-Target Cancer Therapy Ref:18089 PROV (CSP) United States Patent Application No. 62/670,210 June 26, 2018 (Co-Inventor) (Inst); OVERCOMING ACQUIRED RESISTANCE TO CHEMOTHERAPY TREATMENTS THROUGH SUPPRESSION OF STAT3 (Inst); SELECTIVE CHEMOTHERAPY TREATMENTS AND DIAGNOSTIC METHODS RELATED THERETO (Inst); Soluble FAS ligand as a biomarker of recurrence in thyroid cancer; provisional patent 61/727,519 (Inventor) (Inst)
Other Relationship - EMD Serono; Roche/Genentech
(OPTIONAL) Uncompensated Relationships - Reflexion Medical
 
Terufumi Kato
No Relationships to Disclose
 
Andres Felipe Cardona Zorrilla
Honoraria - Abbvie; Boehringer Ingelheim; Bristol-Myers Squibb; Celldex; Merck Sharp & Dohme; Roche
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Foundation for Clinical and Applied Cancer Research (FICMAC); Foundation Medicine; Merck Sharp & Dohme; Novartis; Roche
Speakers' Bureau - Bristol-Myers Squibb; Foundation for Clinical and Applied Cancer Research (FICMAC); Foundation Medicine; Merck Sharp & Dohme; Novartis; Roche
Travel, Accommodations, Expenses - Boehringer Ingelheim; Bristol-Myers Squibb; Foundation Medicine; Merck Sharp & Dohme; Roche
 
Joanne Wagman
Employment - Merck Sharp & Dohme
 
Xinqun Chen
Employment - Merck Sharp & Dohme
 
Bin Zhao
Employment - Merck Sharp & Dohme
Stock and Other Ownership Interests - Merck Sharp & Dohme
 
Christian Schulz
Consulting or Advisory Role - AstraZeneca; Boehringer Ingelheim; Chugai Pharma Europe; MSD; Roche; Takeda; Takeda
Speakers' Bureau - AstraZeneca; Boehringer Ingelheim; Novartis; Roche
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Novartis (Inst); Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; Boehringer Ingelheim; Roche; Takeda